Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Acute myeloid leukemia with t(8;21) /AML1-ETO-positive (AE AML) is a heterogeneous disease
entailing different prognoses. There were significant differences in the therapeutic effect
between different subgroups of AE AML. Therefore, risk stratification-directed therapy is
very necessary for AE AML.